RT Journal Article
SR Electronic
T1 STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study Protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.06.22273514
DO 10.1101/2022.04.06.22273514
A1 van der Feltz-Cornelis, Christina M.
A1 Sweetman, Jennifer
A1 Allsopp, Gail
A1 Attree, Emily
A1 Crooks, Michael G.
A1 Cuthbertson, Daniel J
A1 Forshaw, Denise
A1 Gabbay, Mark
A1 Green, Angela
A1 Heightman, Melissa
A1 Hillman, Toby
A1 Hishmeh, Lyth
A1 Khunti, Kamlesh
A1 Lip, Gregory Y.H.
A1 Lorgelly, Paula
A1 Montgomery, Hugh
A1 Strain, W. David
A1 Wall, Emma
A1 Watkins, Caroline
A1 Williams, Nefyn
A1 Wootton, Dan G.
A1 Banerjee, Amitava
YR 2022
UL http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273514.abstract
AB Introduction As mortality rates from COVID-19 disease fall, the high prevalence of long-term sequelae (Long COVID) is becoming increasingly widespread, challenging healthcare systems globally. Traditional pathways of care for Long Term Conditions (LTCs) have tended to be managed by disease-specific specialties, an approach that has been ineffective in delivering care for patients with multi-morbidity. The multi-system nature of Long COVID and its impact on physical and psychological health demands a more effective model of holistic, integrated care. The evolution of integrated care systems (ICSs) in the UK presents an important opportunity to explore areas of mutual benefit to LTC, multi-morbidity and Long COVID care. There may be benefits in comparing and contrasting ICPs for Long COVID with ICPs for other LTCs.Methods and analysis This study aims to evaluate health services requirements for ICPs for Long COVID and their applicability to other LTCs including multi-morbidity and the overlap with medically not yet explained symptoms (MNYES). The study will follow a Delphi design and involve an expert panel of stakeholders including people with lived experience, as well as clinicians with expertise in Long COVID and other LTCs. Study processes will include expert panel and moderator panel meetings, surveys, and interviews. The Delphi process is part of the overall STIMULATE-ICP programme, aimed at improving integrated care for people with Long COVID.Ethics and dissemination Ethical approval for this Delphi study has been obtained (Research Governance Board of the University of York) as have approvals for the other STIMULATE-ICP studies. Study outcomes are likely to inform policy for ICPs across LTCs. Results will be disseminated through scientific publication, conference presentation and communications with patients and stakeholders involved in care of other LTCs and Long COVID.Registration Researchregistry: https://www.researchregistry.com/browse-the-registry#home/registrationdetails/6246bfeeeaaed6001f08dadc/.Gap There is no general model for providing ICPs to many LTCs, especially in case of multi-morbidity or MNYES.Solution We will develop policy recommendations for such ICPs based upon a Delphi process exploring the value and interchangeability of elements of ICPs for Long COVID. This will help patients and clinicians navigate access to, or provide ICPs for, LTCs.Strengths A key tenet is that people with lived experience of Long COVID or an LTC will be involved from inception in the design and conduct of the study.Weaknesses Possible under-representation of digitally hard to reach groups, although efforts will be made to ensure that data collection is widely inclusive, following the NIHR INCLUDE framework.Competing Interest StatementEA is clinical lead in a Quality Improvement Support Team for Central Camden PCN. MG is funded in part by NIHR Applied Research Collaboration NWC. TH received travel and accommodation in UK to facilitate a talk for Multiple Sclerosis Debating Society and an honorarium payment related to the Acute and General Medicine Conference. GL is Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo; no fees are received personally. HM has received funding from AstraZeneca related to use of monoclonal antibodies in acute COVID-19 treatment, from Millfield Medical in relation to the development of a new CPAP machine for use in hypoxic ventilatory failure, and from Axcella Health Inc about possible new therapeutics. He has delivered paid lectures to legal groups about Long Covid, received support to attend meetings as part of consultancy for AstraZeneca, participated on advisory boards for AstraZeneca and Axcella Health. HM has been involved as Chair, UK National Covid Critical Care Committee; Trustee, UK Intensive Care Society and has stock options with Millfield Medical Ltd. WDS has received research grants from AstraZeneca, Bayer, Novartis, Novo Nordisk and Takeda, and speaker and/or advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Mundi-Pharma, Napp, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier and Takeda. DJC has received investigator-initiated research funding, conference and/or consultancy fees from NovoNordisk, Astra Zeneca and Ipsen. CW has had recent involvement with nine UK-based grants, has contributed to five advisory boards and been involved with six project groups or committees in a leadership or fiduciary capacity. CW has been involved with six NIHR collaborations/projects, of which STIMULATE-ICP is one. NW is a member of NIHR HTA Programme Funding Committee (commissioned research). DGW is supported by an NIHR Advanced Fellowship; University of Liverpool receives an NHS hourly rate for his consultancy work with an NHS Advancing Quality Alliance programme; he has no conflicts of interest. All other authors have no conflicts of interest to report.Funding StatementThis research is funded by NIHR (COV-LT2-0043) as part of the STIMULATE-ICP study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This Delphi study was reviewed and approved by the University of York Department of Health Sciences Research Governance Committee in December 2021 (HSRGC/2021/478/A:STIMULATE).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper; no data are available from this work at present.